PMC:7696151 / 75834-77846
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2242 | 822-839 | Gene | denotes | estrogen receptor | Gene:2099 |
| 2243 | 55-60 | Species | denotes | human | Tax:9606 |
| 2244 | 991-995 | Species | denotes | mice | Tax:10090 |
| 2245 | 1082-1086 | Species | denotes | mice | Tax:10090 |
| 2246 | 121-124 | Chemical | denotes | HCQ | MESH:D006886 |
| 2247 | 385-388 | Chemical | denotes | HCQ | MESH:D006886 |
| 2248 | 422-432 | Chemical | denotes | Epirubicin | MESH:D015251 |
| 2249 | 652-655 | Chemical | denotes | HCQ | MESH:D006886 |
| 2250 | 903-912 | Chemical | denotes | tamoxifen | MESH:D013629 |
| 2251 | 975-978 | Chemical | denotes | HCQ | MESH:D006886 |
| 2252 | 1008-1013 | Chemical | denotes | water | MESH:D014867 |
| 2253 | 1062-1071 | Chemical | denotes | tamoxifen | MESH:D013629 |
| 2254 | 1127-1130 | Chemical | denotes | HCQ | MESH:D006886 |
| 2255 | 1244-1247 | Chemical | denotes | HCQ | MESH:D006886 |
| 2256 | 1277-1288 | Chemical | denotes | vemurafenib | MESH:D000077484 |
| 2257 | 1393-1396 | Chemical | denotes | HCQ | MESH:D006886 |
| 2258 | 1412-1419 | Chemical | denotes | CCI-779 | MESH:C401859 |
| 2259 | 1596-1599 | Chemical | denotes | HCQ | MESH:D006886 |
| 2260 | 1839-1842 | Chemical | denotes | HCQ | MESH:D006886 |
| 2261 | 9-15 | Disease | denotes | cancer | MESH:D009369 |
| 2262 | 31-38 | Disease | denotes | ovarian | MESH:D010049 |
| 2263 | 61-74 | Disease | denotes | breast cancer | MESH:D001943 |
| 2264 | 143-148 | Disease | denotes | tumor | MESH:D009369 |
| 2265 | 304-310 | Disease | denotes | cancer | MESH:D009369 |
| 2266 | 392-398 | Disease | denotes | cancer | MESH:D009369 |
| 2267 | 452-465 | Disease | denotes | breast cancer | MESH:D001943 |
| 2268 | 609-615 | Disease | denotes | cancer | MESH:D009369 |
| 2269 | 744-749 | Disease | denotes | tumor | MESH:D009369 |
| 2270 | 849-863 | Disease | denotes | breast cancers | MESH:D001943 |
| 2271 | 1046-1052 | Disease | denotes | cancer | MESH:D009369 |
| 2272 | 1116-1125 | Disease | denotes | carcinoma | MESH:D009369 |
| 2273 | 1205-1210 | Disease | denotes | tumor | MESH:D009369 |
| 2274 | 1503-1517 | Disease | denotes | melanoma tumor | MESH:D008545 |
| 2275 | 1538-1543 | Disease | denotes | tumor | MESH:D009369 |
| 2276 | 1639-1665 | Disease | denotes | chemoresistant lung cancer | MESH:D008175 |
| 2277 | 1683-1689 | Disease | denotes | cancer | MESH:D009369 |
| 2278 | 1695-1702 | Disease | denotes | hypoxic | MESH:D000860 |
| 2279 | 1746-1752 | Disease | denotes | cancer | MESH:D009369 |
| 2280 | 1905-1910 | Disease | denotes | tumor | MESH:D009369 |
| 2281 | 2000-2005 | Disease | denotes | tumor | MESH:D009369 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T149 | 9-15 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T150 | 61-74 | Phenotype | denotes | breast cancer | http://purl.obolibrary.org/obo/HP_0003002 |
| T151 | 143-148 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T152 | 304-310 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T153 | 392-398 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T154 | 452-465 | Phenotype | denotes | breast cancer | http://purl.obolibrary.org/obo/HP_0003002 |
| T155 | 609-615 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T156 | 744-749 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T157 | 849-863 | Phenotype | denotes | breast cancers | http://purl.obolibrary.org/obo/HP_0003002 |
| T158 | 1046-1052 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T159 | 1116-1125 | Phenotype | denotes | carcinoma | http://purl.obolibrary.org/obo/HP_0030731 |
| T160 | 1205-1210 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T161 | 1503-1511 | Phenotype | denotes | melanoma | http://purl.obolibrary.org/obo/HP_0002861 |
| T162 | 1512-1517 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T163 | 1538-1543 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T164 | 1654-1665 | Phenotype | denotes | lung cancer | http://purl.obolibrary.org/obo/HP_0100526 |
| T165 | 1683-1689 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T166 | 1746-1752 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
| T167 | 1905-1910 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T168 | 2000-2005 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T486 | 0-155 | Sentence | denotes | In other cancer types, such as ovarian, prostatic, and human breast cancer, the anticancer or pro-tumorigenic effects of HCQ are determined by tumor stage. |
| T487 | 156-326 | Sentence | denotes | In the early stages of the disease, the inhibition of autophagy results in an inhibition of tumorigenesis, while in the advanced phase, it enhances cancer survival [145]. |
| T488 | 327-421 | Sentence | denotes | Then, it is important in assessing the contextual role of HCQ in cancer resistance mechanisms. |
| T489 | 422-528 | Sentence | denotes | Epirubicin in triple-negative breast cancer therapy often lost efficacy, due to chemoresistance acquiring. |
| T490 | 529-630 | Sentence | denotes | It has been shown that this cytotoxic agent induced autophagic flux, increasing cancer cell survival. |
| T491 | 631-808 | Sentence | denotes | The combination with HCQ (120 mg/kg by i.p.), thanks to the anti-autophagic properties, significantly suppressed tumor growth by up to 50% with respect to the monotherapy [142]. |
| T492 | 809-950 | Sentence | denotes | In addition, estrogen receptor-positive breast cancers developed resistance to treatment with tamoxifen, due to the enhancement of autophagy. |
| T493 | 951-1078 | Sentence | denotes | The coadministration of HCQ (1–2 mg/day/mice in drinking water) restored the susceptibility of cancer cells to tamoxifen [146]. |
| T494 | 1079-1347 | Sentence | denotes | In mice with thyroid gland xenograft carcinoma, HCQ (150 mg/kg/day p.o. for two weeks) did not provide significant results on tumor growth, while the combination of HCQ with the chemotherapic agent vemurafenib potentiated the anticancer properties of both drugs [147]. |
| T495 | 1348-1595 | Sentence | denotes | Similarly, the two weeks coadministration of HCQ (65 mg/kg) and CCI-779 resulted in a synergism that significantly enhanced their in vivo activity against melanoma tumor growth, in terms of tumor size, with respect to their single treatment [148]. |
| T496 | 1596-1666 | Sentence | denotes | HCQ was revealed also to be active against chemoresistant lung cancer. |
| T497 | 1667-1838 | Sentence | denotes | In this type of cancer, the hypoxic conditions led to lesser susceptibility of cancer cells towards lymphocyte T-mediated cytolysis, thanks to the activation of autophagy. |
| T498 | 1839-2012 | Sentence | denotes | HCQ intake, at doses of 30 mg/kg/day i.p. for 10 days, sensitized tumor cells to lysis and allowed, together with conventional treatment, the eradication of the tumor [149]. |